AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16149682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
Number of subjects: 28
Study 16149682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tear)
Number of subjects: 28
Study 12027232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24
Study 12027232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 24
Study 12027232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24
Study 12027232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 24
Study 10396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex 0.10 ml/kg
Number of subjects: 52
Study 10396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex 0.15 ml/kg
Number of subjects: 52
Study 10396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex 0.20 ml/kg
Number of subjects: 52
Study 10396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex (all doses)
Number of subjects: 52
Study 7601013 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 2123909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg body weight per 10 min)
Number of subjects: 50
Study 2123909 — intervention group
Group type: COMPARATOR
Intervention: Intravenous flecainide (2 mg/kg per 10 min)
Number of subjects: 50
Study 7007057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 5
Study 7007057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30704531 — intervention group
Group type: EXPERIMENTAL
Intervention: READ anti-stigma training for medical students
Number of subjects: 0
Study 30704531 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard teaching without READ training)
Number of subjects: 0
Study 27647529 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA) provided via patient portal
Number of subjects: 0
Study 27647529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 0
Study 27647529 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA)
Number of subjects: 0
Study 25973934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) 200mg/kg/d
Number of subjects: 190
Study 25973934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 22841452 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (loading dose: 1mg/kg, CRI: 0.69mg/kg/h for 2h)
Number of subjects: 9
Study 22841452 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine (loading dose: 80μg/kg, CRI: 30μg/kg/h for 2h)
Number of subjects: 9
Study 22841452 — intervention group
Group type: COMPARATOR
Intervention: Romifidine vs Xylazine during CRI
Number of subjects: 9
Study 21199965 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil and antidepressant therapy
Number of subjects: 130
Study 21199965 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 130
Study 21199965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 21199965 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil in mild cognitive impairment subgroup
Number of subjects: 130
Study 21199965 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal cognition subgroup
Number of subjects: 130
Study 19880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (initial treatment)
Number of subjects: 0
Study 19880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent randomized trials (switching or augmenting treatments)
Number of subjects: 0
Study 19880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vigorous medication trials
Number of subjects: 0
Study 19880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated medication regimens
Number of subjects: 0
Study 17079401 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the parietal layer of the ulnar bursa during open carpal tunnel decompression (57 patients)
Number of subjects: 118
Study 17079401 — intervention group
Group type: COMPARATOR
Intervention: Division of the ulnar bursa during open carpal tunnel decompression (61 patients)
Number of subjects: 118
Study 17079401 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the ulnar bursa
Number of subjects: 118
Study 14652833 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 171
Study 14652833 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 171
Study 14652833 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 171
Study 11708736 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-oriented intervention
Number of subjects: 110
Study 11708736 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 9516030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 0.5 g
Number of subjects: 11
Study 9516030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 11
Study 9516030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g
Number of subjects: 11
Study 9516030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7816383 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope method
Number of subjects: 70
Study 7816383 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptake index method
Number of subjects: 70
Study 7816383 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral method
Number of subjects: 70
Study 7816383 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptake index method (alpha/UI)SR
Number of subjects: 70
Study 7816383 — intervention group
Group type: COMPARATOR
Intervention: Correlation of results
Number of subjects: 70
Study 2971603 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg by mouth)
Number of subjects: 547
Study 2971603 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin (2 g intramuscularly)
Number of subjects: 547
Study 2971603 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 547
Study 2971603 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 547
Study 31363961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group (LIG)
Number of subjects: 165
Study 31363961 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 165
Study 30119757 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX intervention (motivational interviewing and problem-solving skills training)
Number of subjects: 258
Study 30119757 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 258
Study 26497696 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief animated intervention delivered at the patients' bedside
Number of subjects: 70
Study 26497696 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 70
Study 24384584 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 0.0125 μg(−1) kg(−1) min
Number of subjects: 42
Study 24384584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22221571 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 0
Study 22221571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBO therapy)
Number of subjects: 0
Study 20598107 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron sucrose (Venofer(®), 200 mg)
Number of subjects: 120
Study 20598107 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulphate (Duroferon(®), 20×100 mg)
Number of subjects: 120
Study 17269905 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research intervention through soccer leagues
Number of subjects: 0
Study 16286670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic L-carnitine L-tartrate supplementation
Number of subjects: 12
Study 16286670 — intervention group
Group type: COMPARATOR
Intervention: Acute L-carnitine L-tartrate supplementation
Number of subjects: 12
Study 16286670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11203580 — intervention group
Group type: COMPARATOR
Intervention: Polylactide (Guidor) resorbable membrane (GA sites)
Number of subjects: 12
Study 11203580 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of polylactide membrane plus polyglactin root‐lining mesh (Vicryl) and demineralized freeze‐dried bone allograft (DFDBA) (GVB sites)
Number of subjects: 12
Study 9302150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg once daily
Number of subjects: 344
Study 9302150 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 344
Study 9302150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 344
Study 9302150 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 344
Study 9302150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 344
Study 9302150 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 344
Study 9302150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin and Ciprofloxacin
Number of subjects: 344
Study 8365829 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (360 micrograms total dose, 90 micrograms per dose, 4 doses)
Number of subjects: 21
Study 8365829 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 21
Study 3534585 — intervention group
Group type: EXPERIMENTAL
Intervention: LMF plus BCG
Number of subjects: 254
Study 3534585 — intervention group
Group type: COMPARATOR
Intervention: Surgical control
Number of subjects: 254
Study 3046300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in non-pregnant women
Number of subjects: 50
Study 3046300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in early-pregnant women
Number of subjects: 50
Study 3046300 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in late-pregnant women
Number of subjects: 50
Study 3046300 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy progression
Number of subjects: 50
Study 3046300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy (late-pregnant women)
Number of subjects: 50
Study 3046300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy (early-pregnant women)
Number of subjects: 50
Study 31833849 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725
Study 31833849 — intervention group
Group type: COMPARATOR
Intervention: Control (D/C plus emtricitabine/tenofovir-disoproxil-fumarate)
Number of subjects: 725
Study 31002213 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight group
Number of subjects: 1310
Study 31002213 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 1310
Study 31002213 — intervention group
Group type: COMPARATOR
Intervention: All BMI groups
Number of subjects: 1310
Study 28388892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training-group (n=35) received 20-weeks of specific neck/shoulder training.
Number of subjects: 69
Study 28388892 — intervention group
Group type: COMPARATOR
Intervention: Reference-group (n=34) received no training.
Number of subjects: 69
Study 25868634 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 955
Study 25868634 — intervention group
Group type: COMPARATOR
Intervention: Fujinon Intelligent Color Enhancement (FICE)
Number of subjects: 955
Study 25868634 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) for polyps <5 mm
Number of subjects: 955
Study 25868634 — intervention group
Group type: COMPARATOR
Intervention: Fujinon Intelligent Color Enhancement (FICE) for polyps <5 mm
Number of subjects: 955
Study 23861241 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week endurance exercise program (EG)
Number of subjects: 21
Study 23861241 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 21566549 — intervention group
Group type: EXPERIMENTAL
Intervention: CST+OS (conventional standard therapy combined with oral supplementation) for 4 months
Number of subjects: 172
Study 21566549 — intervention group
Group type: COMPARATOR
Intervention: CST (conventional standard therapy alone)
Number of subjects: 172
Study 19943706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib, a multi‐tyrosine kinase inhibitor, approved as first‐line therapy in HCC.
Number of subjects: 0
Study 16290015 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline deficiency of protein C
Number of subjects: 30
Study 16290015 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline deficiency of protein S
Number of subjects: 30
Study 16290015 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline deficiency of antithrombin
Number of subjects: 30
Study 16290015 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline D-dimer levels
Number of subjects: 30
Study 15636308 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐Amlodipine 2.5 mg
Number of subjects: 200
Study 15636308 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 200
Study 11376633 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (900 mg once daily)
Number of subjects: 15
Study 11376633 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin (0.4 mg once daily)
Number of subjects: 15
Study 11376633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9207349 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 207
Study 9207349 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 207
Study 9207349 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 207
Study 8356857 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 90
Study 8356857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90
Study 8356857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2892544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of famotidine
Number of subjects: 5
Study 2892544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of famotidine
Number of subjects: 5
Study 30777900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg/2 mL
Number of subjects: 98
Study 30777900 — intervention group
Group type: COMPARATOR
Intervention: Control (2 mL of saline)
Number of subjects: 98
Study 28493369 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg secukinumab
Number of subjects: 51
Study 28493369 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg secukinumab
Number of subjects: 51
Study 28493369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 26265659 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine for 5 days
Number of subjects: 151
Study 26265659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 24093810 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of change (contemplation and preparation)
Number of subjects: 137
Study 24093810 — intervention group
Group type: COMPARATOR
Intervention: Action and maintenance phases
Number of subjects: 137
Study 21360360 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (n = 33)
Number of subjects: 56
Study 21360360 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (n = 23)
Number of subjects: 56
Study 18294484 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 124; 160 mg total, 40 mg orally every 12 hours starting the evening before and ending the morning after the procedure)
Number of subjects: 247
Study 18294484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 123)
Number of subjects: 247
Study 18294484 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 247
Study 16788386 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Global Posture Reeducation method)
Number of subjects: 40
Study 16788386 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional exercise regimen)
Number of subjects: 40
Study 12883898 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 9
Study 12883898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 9
Study 11190646 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed etappenlavage with the Ethizip
Number of subjects: 0
Study 11190646 — intervention group
Group type: COMPARATOR
Intervention: Open dorsoventral interval therapy using the TAC
Number of subjects: 0
Study 11190646 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 9083323 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate-ethinyl estradiol (active OC treatment)
Number of subjects: 250
Study 9083323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 8471696 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg brofaromine twice a day
Number of subjects: 18
Study 8471696 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg phenelzine three times a day
Number of subjects: 18
Study 8471696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3534966 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative total pelvic irradiation (3750 cGy divided into 30 fractions over 12 days, 125 cGy per fraction, three fractions per day)
Number of subjects: 116
Study 3534966 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative total pelvic irradiation plus misonidazole (MISO) (1 g/m2 orally 2 h before the first daily fraction)
Number of subjects: 116
Study 3534966 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (cystectomy alone)
Number of subjects: 116
Study 29490185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone plus Fludrocortisone
Number of subjects: 1241
Study 29490185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1241
Study 26886261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both structured group‐based behavioral health intervention and interpersonal psychotherapy group sessions
Number of subjects: 1014
Study 26886261 — intervention group
Group type: COMPARATOR
Intervention: Single intervention (either structured group‐based behavioral health intervention or interpersonal psychotherapy group sessions)
Number of subjects: 1014
Study 26886261 — intervention group
Group type: COMPARATOR
Intervention: No new interventions
Number of subjects: 1014
Study 24577353 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal transplant from a healthy donor
Number of subjects: 9
Study 22534422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh reinforcement of pancreatic transection (Seamguard or Peristrips Dry)
Number of subjects: 100
Study 22534422 — intervention group
Group type: COMPARATOR
Intervention: No mesh reinforcement
Number of subjects: 100
Study 20435187 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 levels measured at randomization and after 24, 48, and 72 hours
Number of subjects: 403
Study 20435187 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 levels
Number of subjects: 403
Study 17704884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication (NF)
Number of subjects: 140
Study 17704884 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (TF)
Number of subjects: 140
Study 16335887 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day)
Number of subjects: 0
Study 16335887 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (12 mg/day) - up-titrated monotherapy
Number of subjects: 0
Study 16335887 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release nifedipine plus candesartan combination therapy
Number of subjects: 0
Study 16335887 — intervention group
Group type: COMPARATOR
Intervention: Candesartan monotherapy
Number of subjects: 0
Study 16335887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with controlled release nifedipine and low-dose candesartan
Number of subjects: 0
Study 11910308 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan titration to 100 mg
Number of subjects: 90
Study 11910308 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg addition
Number of subjects: 90
Study 9690108 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored feedback
Number of subjects: 0
Study 9690108 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative computer-tailored feedback
Number of subjects: 0
Study 9690108 — intervention group
Group type: COMPARATOR
Intervention: General nutrition information letter (Control)
Number of subjects: 0
Study 7515862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified patient teaching
Number of subjects: 60
Study 7515862 — intervention group
Group type: COMPARATOR
Intervention: General patient teaching
Number of subjects: 60
Study 2573143 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 19
Study 2573143 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 19
Study 2573143 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 4723266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (490 mg base) via intravenous infusion every 8 hours for 3 days (1.47 gm base daily)
Number of subjects: 12
Study 4723266 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric‐coated tablets of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Number of subjects: 12
Study 4723266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin capsules of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Number of subjects: 12